We are very excited to welcome 2 new fundmanagers, David Zickafoose, which has a strategy uniquely focused on biotech stocks and Jacob Leedgaard focused on Swedish/Scandinavian Stocks.
David has been investing in Biotech for 10 years and works in the industry. He has picked 10 very promising stocks in the small and midcap segment. We look forward to follow him and his stockpicks in the future. Biotech has certainly had a very good year, but with the latest weeks selloff, new opportunities have surfaced.
You can follow David Zickafoose here.
Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities. He will usually search in the small cap space as less analyst coverage increases the chance of mispricing.
You can follow Jacob Leedgaard here.